Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Leukemia

  Free Subscription


15.06.2026

1 Acta Haematol
1 Am J Clin Pathol
3 Ann Hematol
1 Biochem Biophys Res Commun
2 Biochem Pharmacol
4 Blood
3 BMC Cancer
2 Bone Marrow Transplant
1 Genes Chromosomes Cancer
1 Hematol Oncol Clin North Am
1 J Clin Oncol
1 J Pediatr Hematol Oncol
3 Leuk Lymphoma
3 Leukemia


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Haematol

  1. ABDELGAMID M, Hashi NJ, Hefazi M, Matin A, et al
    Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies.
    Acta Haematol. 2026 Jun 8:1-11. doi: 10.1159/000552196.
    PubMed         Abstract available


    Am J Clin Pathol

  2. TORABI A, Fromm JR, Dorer R, Ding Y, et al
    CD48 expression in T-lymphoblastic leukemia/lymphoma and mature T-cell neoplasms: role in detecting measurable residual disease and potential confounders, a single-institution retrospective review.
    Am J Clin Pathol. 2026;165:aqag060.
    PubMed         Abstract available


    Ann Hematol

  3. FILAR B, Bednarczyk M, Czogala W, Garus K, et al
    Acute myeloid leukemia post cytotoxic therapy following medulloblastoma in a child successfully treated with a single cycle of CPX-351 followed by stem cell transplantation - a case report.
    Ann Hematol. 2026 Jun 11. doi: 10.1007/s00277-026-07123.
    PubMed         Abstract available

  4. ZHENG Y, Yu L, Le S, Li N, et al
    KIT and FLT3-ITD mutations do not predict outcomes in pediatric core-binding factor acute myeloid leukemia: findings from the C-HUANAN-AML-15 multicenter cohort study.
    Ann Hematol. 2026 Jun 10. doi: 10.1007/s00277-026-07112.
    PubMed         Abstract available

  5. KRAUSE SW, Bethge W, Bug G, Elmaagacli A, et al
    What is the best path towards allogeneic transplantation in MDS and AML? A survey among German-spreaking centers for allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2026;105:298.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  6. STEFIK P, Durisova K, Spaldova J, Sofrankova L, et al
    Fingolimod induces cytotoxic stress and apoptosis-like cell death in drug-sensitive and P-glycoprotein-overexpressing acute myeloid leukemia cells.
    Biochem Biophys Res Commun. 2026;828:154118.
    PubMed         Abstract available


    Biochem Pharmacol

  7. XIONG Y, Liu J, He C, Qu Z, et al
    Nitazoxanide cooperates with cytarabine to inhibit cytarabine-resistant acute myeloid leukemia progression via mitochondrial dysfunction and PLK1 suppression.
    Biochem Pharmacol. 2026;251.
    PubMed         Abstract available

  8. LIU Q, Zheng W, Yang Y, Liang G, et al
    Pharmacologic modulation of the SAT1-N1-acetylspermidine axis is associated with enhanced chemotherapy cytotoxicity in T-LBL/ALL cells.
    Biochem Pharmacol. 2026;250.
    PubMed         Abstract available


    Blood

  9. FISKUS W, Mill CP, Issa GC, Piel J, et al
    Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.
    Blood. 2026;147:2809-2820.
    PubMed         Abstract available

  10. DOTTI G, Walhart T, Biondi M, Stucchi S Sr, et al
    High-avidity cathepsin-G-specific CAR-T cells for the treatment of acute myeloid leukemia.
    Blood. 2026 Mar 12:blood.2025030577. doi: 10.1182/blood.2025030577.
    PubMed         Abstract available

  11. YANG JJ, Yoshimura S, Actis M, Seffernick JT, et al
    LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia.
    Blood. 2026 Mar 12:blood.2025031127. doi: 10.1182/blood.2025031127.
    PubMed         Abstract available

  12. REN L, Zhang H, Bobileva O, Nai F, et al
    Targeting the METTL1/m(7)G axis as a therapeutic strategy in myeloid leukemia.
    Blood. 2026 Mar 12:blood.2025030336. doi: 10.1182/blood.2025030336.
    PubMed         Abstract available


    BMC Cancer

  13. EL ACHKAR H, Bazarbachi A, Chakhachiro Z, Mahfouz R, et al
    High-risk cytogenetic abnormalities impact the cytological and clinical behavior of core binding factor acute myeloid leukemia: a case-control study.
    BMC Cancer. 2026 Jun 8. doi: 10.1186/s12885-026-16281.
    PubMed         Abstract available

  14. RADWAN SM, Mostafa D, Radwan RA, Elghobary HA, et al
    Upregulation of NFS1 and downregulation of GSDMD as prognostic biomarkers in acute myeloid leukemia: implications for diagnosis and therapeutic strategies.
    BMC Cancer. 2026;26:739.
    PubMed         Abstract available

  15. MA B, Zhang L
    Prognostic significance of therapy-induced senescence and SASP dynamics in acute myeloid leukemia: a retrospective cohort study.
    BMC Cancer. 2026 Jun 10. doi: 10.1186/s12885-026-16171.
    PubMed         Abstract available


    Bone Marrow Transplant

  16. BARBULLUSHI K, Gagelmann N, Rathje K, Badbaran A, et al
    Outcomes of allogeneic transplantation in blast-phase myeloproliferative neoplasms: one-third achieve long-term survival.
    Bone Marrow Transplant. 2026;61:740-746.
    PubMed         Abstract available

  17. MAAS-BAUER K, Meyer T, Yucel M, Garofalaki M, et al
    Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2026;61:677-684.
    PubMed         Abstract available


    Genes Chromosomes Cancer

  18. GARCIA R, Xu J, Yu L, Srinivasan K, et al
    Cytogenetic and Molecular Analysis of a "Double-Hit" RUNX1 Including a RUNX1 p.Trp279* and a Cryptic Novel t(6;21)(q25;q22)/RUNX1::ARID1B in Acute Myeloid Leukemia.
    Genes Chromosomes Cancer. 2026;65:e70148.
    PubMed         Abstract available


    Hematol Oncol Clin North Am

  19. ZARNEGAR-LUMLEY S, McNeer JL
    Updates in Childhood Acute Lymphoblastic Leukemia.
    Hematol Oncol Clin North Am. 2026;40:331-346.
    PubMed         Abstract available


    J Clin Oncol

  20. ISSA GC, Cuglievan B, El Hajjar G, Jen WY, et al
    The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE).
    J Clin Oncol. 2026 Jun 11:101200JCO2601159. doi: 10.1200/JCO-26-01159.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  21. COCHRAN TR, Fulbright J, Butrous S, Lee B, et al
    Frailty in Children and Adolescents With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Receiving Maintenance Chemotherapy-A Pilot Study.
    J Pediatr Hematol Oncol. 2026 Jun 11. doi: 10.1097/MPH.0000000000003217.
    PubMed         Abstract available


    Leuk Lymphoma

  22. FRADIN JJ, Rein L, Szabo A, Carlson KS, et al
    Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy.
    Leuk Lymphoma. 2026 Jun 11:1-9. doi: 10.1080/10428194.2026.2684259.
    PubMed         Abstract available

  23. ALHAJAHJEH A, Beke KE, Grimshaw AA, Aguirre LE, et al
    Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.
    Leuk Lymphoma. 2026 Jun 7:1-13. doi: 10.1080/10428194.2026.2682397.
    PubMed         Abstract available

  24. LEVY YURKOVSKI I, Kreiniz N, Peleg-Nesher S, Koren L, et al
    Sexual health and intimacy concerns among patients with chronic lymphocytic leukemia: a cross-sectional needs assessment study.
    Leuk Lymphoma. 2026 Jun 5:1-9. doi: 10.1080/10428194.2026.2682282.
    PubMed         Abstract available


    Leukemia

  25. OLIVEIRA ML, Nuantang K, Hure G, Avila-Avila A, et al
    A novel CD7-directed antibody-drug conjugate targeting BCL-XL with potent anti-leukemic activity in T-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Jun 8. doi: 10.1038/s41375-026-02998.
    PubMed         Abstract available

  26. PICIOCCHI A, Talone A, Messina M, de Fabritiis P, et al
    Normal life expectancy after all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Leukemia. 2026 Jun 8. doi: 10.1038/s41375-026-02989.
    PubMed        

  27. AL-ALI HK, Heidel ST, Palandri F, Heidel FH, et al
    MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.
    Leukemia. 2026;40:1111-1121.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum